INTRODUCTION
The microflora that colonize the human intestine are separated from the immune system by a layer of tightly connected epithelial cells. Yet, these enterocytes allow leakage of small quantities of bacterial products from the gut lumen to extra-intestinal locations like the underlying mucosal tissue, mesenteric lymph nodes, peripheral blood or the liver, a process defined as microbial translocation (Brenchley & Douek, 2012) . Balanced translocation of immunostimulatory bacterial products to the mucosa is crucial for proper development of the immune system (Brenchley & Douek, 2012) . Damage to the epithelial barrier is characterized by up-regulation of soluble CD14 (sCD14) levels in blood (Brenchley et al., 2006 (Brenchley et al., , 2008 Sandler et al., 2011b) . Sustained increased microbial translocation may result in chronic systemic immune activation (Brenchley & Douek, 2012) , which may ultimately lead to immune exhaustion and loss of immune function (Dyavar Shetty et al., 2012) .
In human immunodeficiency virus (HIV) patients, the relation between sCD14 and microbial translocation is widely studied (Brenchley & Douek, 2012) . Mechanisms that underlie increased microbial translocation include a diminished function of the epithelial barrier by increased enterocyte death and damage to the tight junctions. Additionally, the simian immunodeficiency virus (SIV) infection model showed that CD4 + Th17 cells are the primary target cells during acute SIV infection. Depletion of these cells from the underlying mucosal tissue results in impaired immune surveillance, wider dissemination of bacterial products and systemic immune activation. Taken together, persistent immune activation during HIV pathogenesis is caused by increased microbial translocation (Fig. 1) .
The relationship between microbial translocation and pathogenesis during chronic HCV infection is less well understood. There are several lines of evidence that support an association between microbial translocation and liver fibrosis. It is well acknowledged that liver fibrosis is accelerated in patients with HCV/HIV co-infection compared to HCV mono-infection (Mastroianni et al., 2014) , and increased levels of sCD14 were reported in HIV/HCV co-infected patients (Marchetti et al., 2014; Sacchi et al., 2014) . However, elevated sCD14 was also observed in HCV monoinfected patients in the presence (Sandler et al., 2011a) and absence (Marchetti et al., 2012) of liver fibrosis. These findings suggest a multifactorial process: (1) chronic liver disease may diminish clearance of translocated bacterial products by hepatic dysfunction (Balagopal et al., 2008) ; (2) increased pressure in the portal vein may increase intestinal permeability and microbial translocation (Mehta et al., 2014) ; and (3) immunostimulatory bacterial products may contribute to liver fibrosis (Seki & Schnabl, 2012) .
To our knowledge, all experiments studying microbial translocation in relation to HCV infection have been performed on human subjects. Here, we investigated microbial translocation in chimpanzees (Pan troglodytes) that were previously used in HCV and HIV/SIV studies. Animals used for these types of studies are typically healthy individuals without underlying immune disorders or infectious diseases. In addition, lifelong conditioned housing warrants comparable environmental factors in terms of lifestyle, diet without alcohol intake and additional circumstances that have been described to contribute or affect intestinal permeability, microbial translocation and composition of the gut microflora (Bataller & Lemon, 2012; Pinzone et al., 2012) .
Chimpanzees are the only animal model validated to study HCV infection. Like humans, HCV exposure in chimpanzees leads to a spontaneously resolving infection, or the virus persists and the animals become chronically infected. Unlike in humans, hepatic fibrosis as a result of HCV infection has not been documented in chimpanzees (Bataller & Lemon, 2012; Bukh, 2012; Houghton, 2009; Lanford et al., 2001; Walker, 1997) . Therefore, HCV-infected chimpanzees offer a unique opportunity to investigate microbial translocation in a host without liver fibrosis.
The aim of this study was to investigate microbial translocation in HCV-infected chimpanzees. As HIV infection in humans is associated with microbial translocation and systemic immune activation, HIV/SIV-infected chimpanzees were also included. Additionally, the impact of liver fibrosis on microbial translocation was addressed by direct comparison between chimpanzees with high HCV load and human patients with advanced fibrosis.
Our data show that in HIV/SIV-infected chimpanzees, sCD14 up-regulation was accompanied by increased microbial translocation. Elevated levels of sCD14 were also observed in humans with advanced fibrosis and in chimpanzees with sustained high HCV load. However, evidence for increased microbial translocation was only found in a minority of the patients.
RESULTS

No signs of liver fibrosis in chimpanzees
There is a worldwide consensus on the lack of progressive hepatic fibrosis after HCV infection in chimpanzees (Bataller & Lemon, 2012; Bukh, 2012; Houghton, 2009; Lanford et al., 2001; Walker, 1997) .
Taking liver biopsies from chimpanzees is an invasive procedure that requires ethical considerations and approval from the institute's ethical committee. At the time, these animals were housed at the Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands, and needle biopsies were justified only in the context of specific research questions during a study and not as part of regular healthcare checks. As a consequence, liver biopsies were only available from a limited number of animals. In humans with advanced HCV infection, hepatic fibrosis is characterized by alterations in liver architecture due to hepatocyte death and deposition of extracellular matrix ( Fig. 2a-d) . Hepatic tissue from seven adult chimpanzees, over 10 years after HCV genotype 1 infection, was also examined for signs of fibrosis. In these biopsies, mild lymphocyte infiltrates were found, mainly located not only in the portal areas but also scattered throughout the liver (Fig. 2e-h ). No sign of vascular construction was observed and the hepatic bile ducts were regularly shaped. The data suggest that no fibrosis was present in the livers of these chimpanzees.
Increased sCD14 is associated with HIV and HCV infection
Lipopolysaccharide (LPS) is a glycolipid of the outer cell wall of Gram-negative bacteria. When LPS is detected in peripheral blood, an acute inflammatory response is induced. This response is initiated via TLR4 triggering of the membranebound CD14 (mCD14) on monocytes. To prevent monocyte overstimulation, the non-signalling decoy molecule sCD14 is produced and similar to mCD14, sCD14 can bind the LPS-LPS binding protein complex. sCD14 is produced in the liver and detectable in serum. sCD14 is widely used as a marker for LPS-induced monocyte activation (Abad-Fern andez et al., 2013; Balagopal et al., 2008; French et al., 2013; Kristoff et al., 2014) .
Here, we used sCD14 as a first indication for LPS-induced monocyte activation. In patients with advanced fibrosis (F3/ F4), the levels of sCD14 were significantly higher (P=0.021) compared to healthy controls, median 4774 ng ml À1 (ranging from 2624 to 6785 ng ml
À1
) and 1712 ng ml À1 (ranging from 1084 to 7328 ng ml À1 ), respectively (Fig. 3a) .
Since chimpanzees do not develop progressive liver fibrosis following HCV infection, it was not possible to discriminate based on fibrosis status. It was, however, reported that before treatment an IP-10 level below 600 pg ml À1 is a good prognostic marker for successful IFN-based treatment in patients (Darling et al., 2011) . We previously reported that IP-10 levels in chimpanzees strongly correlate with HCV load (Verstrepen et al., 2012) . Therefore, based on virus load, chronically infected chimpanzees can be divided into two groups: (1) animals with a virus load consistently higher than 200 IU ml À1 and (2) animals with a virus load consistently lower than 200 IU ml À1 .
When sCD14 levels were measured in chimpanzees, the levels in serum were substantially lower compared to humans (data not shown). No difference was observed between naive chimpanzees and chimpanzees during acute HCV infection or animals with a low HCV load (data not shown). By contract, when naive and chimpanzees with a high virus load were compared, a modest but significant increase in sCD14 levels was observed in the HCV-infected animals (P=0.032) (Fig. 3b ). Since HIV-related pathogenesis in humans is associated with microbial translocation, it would be interesting to investigate microbial translocation in HIV/ SIV-infected chimpanzees. Therefore, animals that were infected for over 4 years were included. Also in these chimpanzees up-regulation of sCD14 was observed (P=0.0014).
Signs of disrupted gut barrier integrity after HIV but not HCV infection
The microflora in the gut is separated from the underlying mucosal tissue by the intestinal barrier. When this barrier becomes more permeable, more immunostimulatory molecules leak into the mucosal tissue. The main cells in the barrier are enterocytes. When the barrier function is disrupted due to apoptosis of the enterocytes, intestinal fatty acid- binding protein (I-FABP) is released into peripheral blood. I-FAPB levels in serum are used as an indicator for damaged enterocytes and a measure for microbial translocation (French et al., 2013; Sandler et al., 2011b) .
In humans, HIV infection is known to affect enterocytes (Brenchley & Douek, 2012) . To investigate whether elevated levels of sCD14 in HIV/SIV-infected animals were caused by increased permeability of the barrier, I-FABP levels were quantified in HIV/SIV-infected chimpanzees. Similar to HIV-infected humans, I-FABP was elevated in HIV/SIVinfected chimpanzees compared to thosec with high HCV load (P<0.0001), those with low HCV load (P<0.0001) and animals with acute HCV infection (P=0.009) (Fig. 4) . Due to two outliers, no significant difference was reached between naive animals and HIV/SIV-infected animals. No difference was observed between naive animals and HCVinfected chimpanzees.
Also in HCV disease progressors, increased levels of I-FABP were described (French et al., 2013) . However, in the patients studied here, no statistically significant difference was observed between healthy controls and patients with mild or advanced fibrosis (Fig. 4) .
These data imply that neither HCV infection nor HCVinduced fibrosis affects the permeability of the intestinal barrier due to enterocyte apoptosis.
LBP correlates with HIV infection in chimpanzees
sCD14 is an indirect technique used to quantify monocyte stimulation by LPS. To determine whether the elevated levels of sCD14 were indeed caused by immunostimulatory molecules of translocated bacteria from the gut, we aimed to measure LPS. However, direct quantification of LPS in stored serum is technically complicated and data are unreliable when samples have been in contact with polypropylene (Roslansky et al., 1991) . Since all samples used in this study were stored in polypropylene ampoules, quantification of LPS was not the preferred technique. Instead, LBP was determined as a surrogate marker. LBP is predominantly produced by hepatocytes and, in order to initiate monocyte activation, LBP chaperones LPS to mCD14 and TLR4. In addition to LBP, EndoCab was determined. The EndoCab assay measures antibodies that are directed against the core antigen of LPS (Balagopal et al., 2008; French et al., 2013) . Both LBP and EndoCab are often used as an alternative for the quantification of LPS (Balagopal et al., 2008; Brenchley et al., 2006; French et al., 2013) .
To investigate whether sCD14 up-regulation in HIV/SIVinfected chimpanzees was a direct effect of microbial translocation, we determined EndoCab and LPS levels. EndoCab was lower in HIV/SIV-infected chimpanzees compared to healthy controls (Fig. 5a ), although this difference was not significant. ), high HCV load (consistently >200 000 IU ml
À1
) and HIV/SIV (black dots). Lines represent the median values. P-values were calculated using non-parametric, unpaired, two-tailed t-tests. *P 0.05, **P 0.01.
In concordance with the up-regulated sCD14 levels and increased death of enterocytes observed in HIV/SIVinfected chimpanzees, a small but significant up-regulation of LBP was observed (P=0.034) (Fig. 5b) . This implies that in these animals, sCD14 up-regulation was indeed accompanied by increased levels of LPS.
In HCV-infected patients and chimpanzees, no correlation was found between sCD14 and either EndoCab (Fig. 5a) or LBP (Fig. 5b) , suggesting that, sCD14 up-regulation was not a direct effect of microbial translocation.
DISCUSSION
In humans, HIV infection is associated with increased permeability of the gut barrier allowing translocation of immunostimulatory molecules from the gut lumen to the underlying mucosa. Also, in HCV-infected patients increased levels of sCD14 have been described, but the mechanism behind this remains still unclear.
Currently available data on microbial translocation during HCV were obtained from studies in humans. Here, we investigated sCD14 and microbial translocation in chimpanzees. The controlled environmental housing conditions of the animals circumvent differences in lifestyle, diet and other variables that have been described as affecting natural variation in microbial translocation (Pinzone et al., 2012) . Microbial translocation and systemic immune activation were studied in parallel among HIV/SIV-infected chimpanzees, HCV-infected chimpanzees and HCVinfected humans. In this way the impact of different viral infections, as well as the association between hepatic fibrosis and microbial translocation, could be studied.
The data reported here show up-regulated levels of sCD14 in HIV/SIV-infected chimpanzees. This was accompanied by high levels of I-FABP, indicating that up-regulation of sCD14 was indeed the result of increased permeability of the epithelial barrier due to enterocyte apoptosis. This was confirmed by slightly higher levels of LBP, a protein that is known to chaperone LPS from gut bacteria to either mCD14 or sCD14. These finding are in acconcord with findings in HIV-infected humans (Brenchley et al., 2006) . Excessive microbial translocation is seen as a characteristic of AIDS in humans and is not observed in non-pathogenic SIV infections in sooty mangabeys (Cercocebus atys) or African green monkeys (Chlorocebus sabaeus) (Marchetti et al., 2013) . Although HIV does generally not cause AIDS in chimpanzees, some cases of pathogenic infections with HIV in chimpanzees have been reported (Juompan et al., 2008; Keele et al., 2009; Novembre et al., 1997) . In the HIV/SIV-infected animals tested here, the loss of epithelial integrity in the gut is similar to what is seen in HIV patients progressing to AIDS, and in macaques infected with pathogenic SIV strains (Brenchley et al., 2006; Kristoff et al., 2014; M arquez et al., 2015) . Th17 cells in the gut mucosa are the primary target cells for HIV and SIV in humans and macaques (Dandekar et al., 2010; Favre et al., 2009) . Depletion of these cells is believed to lead to systemic in humans (open dots) and chimpanzees (filled dots). Analysed were HCV-negative human controls, chronic HCV carriers with F0/F1 and patients with F3/F4. Naive chimpanzees were compared to animals with acute HCV infection, chronic HCV infection with low virus load (consistently <200 000 IU ml À1 ), chronic HCV infection with high virus load (consistently >200 000 IU ml
À1
) and HIV/SIV infection. Lines represent the median values. P-values were calculated using non-parametric, unpaired, twotailed t-tests. *P 0.05, **P 0.01.
immune activation (Brenchley et al., 2008) . It would, therefore, be interesting to study whether Th17 cells are targeted by HIV or SIV in chimpanzees.
In the chimpanzees with sustained high HCV load, significantly higher levels of sCD14 were observed compared to naive animals. In contrast to humans, it is acknowledged that chronic HCV infection does not cause progressive liver fibrosis in chimpanzees (Bataller & Lemon, 2012; Bukh, 2012; Houghton, 2009; Lanford et al., 2001; Walker, 1997) . Histological examination of liver sections showed no indication of hepatic fibrosis in HCV-infected chimpanzees. This strongly suggests that sCD14 up-regulation occurs in the absence of liver fibrosis. As shown by the normal levels of I-FABP, the layer of enterocytes remained intact and no difference was found in LBP levels between naive and HCV-infected chimpanzees. Together this implies that the up-regulation of sCD14 was not caused by microbial translocation.
The findings in HCV-infected chimpanzees with sustained high virus load resemble the observations in humans with advanced fibrosis. Also in these patients, the elevated levels of sCD14 could not be explained by enterocyte death and no up-regulation of LBP was observed.
The up-regulation of sCD14 without signs of microbial translocation, observed in human progressors and chimpanzees with sustained high virus load, raised new questions. It is tempting to speculate that immunostimulatory molecules are less efficiently cleared from the circulation, even in the absence of liver fibrosis. On the other hand, sCD14 may be produced in response to HCV replication. Ex vivo studies have, however, shown that human hepatocytes produce sCD14 (Su et al., 1999) , and studies in the chimeric mouse model demonstrated that HCV infection does not promote sCD14 production by human hepatocytes (Meuleman et al., 2006) . This does, however, not exclude that sCD14 is produced by other cells in the liver. This should be further investigated.
In contrast to HIV, primary target cells of HCV are located in the liver and not in the area where microbial translocation takes place. There is evidence for the presence of HCV proteins in enterocytes, although this is not accompanied by inflammatory responses (Deforges et al., 2004) and therefore, pathophysiological changes in the mucosal barrier are not likely to occur. In this light, the lack of a direct association between HCV infection and microbial translocation is not surprising. However, this does not exclude the potential impact of high tension in the portal vein during liver fibrosis on microbial translocation. Although the median I-FABP level in HCV-infected humans was not significantly different, there were outliers, in both the group of mild liver fibrosis as well as advanced fibrosis. This disparity was less apparent in chronically infected chimpanzees. Variation in epithelial barrier integrity between individual patients was previously reported (Sandler et al., 2011a) , and underlines the complicated molecular mechanisms that are involved in hepatic fibrosis and the response to immunostimulatory molecules (Seki & Schnabl, 2012) . However, based on these data, additional contributing factors, such as difference in diet, lifestyle or underlying disorders, cannot be excluded. Additional research on this subject is required to unravel interrelating mechanisms.
The overall sCD14 levels in chimpanzees were much lower compared to humans. We acknowledge that the sCD14 levels detected in healthy control animals are different from the levels that were recently reported by Greenwood et al. (2015) . This difference may be explained by the individual animals that were included in this study. In our experiments, relatively low levels of sCD14 were confirmed by low levels of LBP. Even upon HIV/SIV infection, up-regulation of sCD14 and LBP was only marginal in chimpanzees. At present, we have no clear explanation for this. It has been described that baseline levels of microbial translocation vary among species and the environment in which one lives (Klatt et al., 2010; Redd et al., 2009) . This may indicate that the innate immune system in chimpanzees is less susceptible to activation by bacterial products compared to humans. However, we have previously shown that monocyte-derived dendritic cells in chimpanzees are susceptible to LPS stimulation (Rollier et al., 2003) . On the other hand, pre-exposure to LPS may lead to tolerance to subsequent LPS stimulation (Lester et al., 2009) .
In humans, IL-6 and sIL-2R in peripheral blood were variably up-regulated (Prince et al., 1988) . In addition, these markers were poorly expressed and not up-regulated during HIV or HCV infection. We currently have no explanation for the lack of systemic immune activation in HIV-infected chimpanzees.
In conclusion, as in HIV-infected patients, HIV/SIVinfected chimpanzees exhibited up-regulated levels of sCD14 due to microbial translocation. Also, in HCVinfected humans and chimpanzees increased levels of sCD14 were observed, but here the outcome could not be explained by microbial translocation, suggesting either that HCV infection can impact liver function even in the absence of liver fibrosis, or that sCD14 is produced in response to HCV infection. This should be a subject for further investigation.
METHODS
Bio-repository. Samples were collected from chronic HCV patients visiting the outpatient clinic of the Erasmus MC, Rotterdam, and stored at À80
C. Relevant clinical and virological details of the individual patients are presented in Table 1 . The institutional ethical review board of the Erasmus MC approved the protocols, and informed consent was obtained from all individuals. The stage of liver fibrosis was determined by METAVIR score on core needle biopsies (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; F4, cirrhosis), and HCV RNA load was determined with COBAS TaqMan assay. Patient samples were divided into two groups, patients with little or no fibrosis (F0/F1) and those with advanced fibrosis (F3/F4).
Samples from chimpanzees used in this study were collected for reasons of health and welfare management or obtained from the BPRC repository. Plasma and serum samples were analysed in parallel and no difference was observed between the two sample types (data not shown). Liver tissue samples were collected post-mortem. As chimpanzees have never been euthanized in the setting of experimental work conducted at the BPRC, liver material was collected from animals that had died from natural causes. Based on the HCV status, chimpanzees were divided into different groups: (1) 'naive': non-infected animals (n=7) serving as healthy controls; (2) acute (n=10), <6 weeks after experimental HCV infection; (3) 'low virus load': HCV-infected animals (n=5) with a virus load consistently lower than 250 000 IU ml
À1
; (4) 'high viral load': HCV-infected animals (n=5) with a virus load consistently higher than 250 000 IU ml
; and (5) 'HIV/SIV': (n=19) chimpanzees that were infected with HIV and/or SIV for more than 4 years.
All HCV chimpanzees were experimentally infected with HCV genotype 1 and HCV RNA load was determined with a ROCHE HCV TaqMan assay. Relevant parameters of patients and chimpanzees are summarized in Table 1 .
Assessment of liver fibrosis. Liver tissue was fixed in 10 % formalin, processed by conventional methods and embedded in paraffin. Fourmicrometre sections were prepared and stained with haematoxylin and eosin using standard procedures. Subsequently, sections were microscopically examined by an experienced pathologist for signs of hepatic fibrosis such as disruption of liver parenchyma architecture, extension of fibres, formation of large fibrous septa, pseudo-lobe separation, collagen deposition and the presence of inflammatory cells.
Quantification of systemic bacterial exposure and immune activation. Commercially available ELISA kits were used to quantify the levels of sCD14 (R&D Systems): I-FABP, LBP and EndoCab (all from Hycult Biotech); IL-6 (Ucytech) and sIL-2R (eBioscience) in stored plasma or serum. All tests were performed according to the manufacturer's guidelines. The assays were performed in duplicate, and data were analysed using ADAMSEL software (BPRC).
Statistical analysis. To determine whether there were significant differences between the different study groups, either unpaired parametric or non-parametric tests were performed (Prism 6.0). Statistical significant differences were defined as P<0.05. 
